Pyrin variant E148Q potentiates inflammasome activation and the effect of pathogenic mutations in cis.

"their clinical histories are presented in supplementary data s1 available at rheumatology online."

"Disclosure statement: S.L.M. is VP of Discovery Biology for NRG Therapeutics, and a Scientific Advisor for Odyssey Therapeutics. The remaining authors have declared no conflicts of interest."

"Funding S.L.M. is supported by Australian National Health and Medical Research Council (NHMRC) Project Grants (2003159, 2003756). T.R. is supported by the Walter and Eliza Hall Coppel PhD Scholarship. T.R. would like also to thank la bourse de formation pour jeunes rhumatologues de la Societe Suisse de Rhumatologie (SSR) and la bourse de formation de l’Hopital cantonal de Fribourg (HFR) for support. Disclosure statement: S.L.M. is VP of Discovery Biology for NRG Therapeutics, and a Scientific Advisor for Odyssey Therapeutics. The remaining authors have declared no conflicts of interest."